Medtronic secures grants for nerve blockage, ECAP control and cardiac pacing technologies.
The filing
On November 10, 2026, Medtronic was granted US patents for nerve blockage with combination stimulation/block therapy for glycemic control, ECAP-based control of electrical stimulation therapy, activity detection for cardiac remodeling pacing, stimulation cycling adjustments based on user input, and an implantable medical lead with shield. On November 12, 2026, Medtronic's applications for a bimetal diffusion bonded electrode, multiple electrode arrangement for therapy, and communication via inductive coupling were published, alongside Covidien LP's application for automatic electrode pair selection of circular phrenic nerve stimulation lead. US20260355509A1 (opens in a new tab) US20260355511A1 (opens in a new tab) US20260355523A1 (opens in a new tab) US20260355526A1 (opens in a new tab)
This filing’s full text wasn’t read for this issue, so its claims and the applicant’s background aren’t shown. Both are in the record, under Sources.